Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology (FERT-ISSUES)

Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.

Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.

However, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.

This project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.

This work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).

Its objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.

This work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.

Study Overview

• Status: Recruiting
• Conditions: Oncology; Live Birth Rate; Fertility Preservation; Assisted Reproductive Technology; Reproductive Health; Cancer Remission; Reproductive Outcomes; Fertility Counseling; Psychological Impact; Fertility Observatory; Patient Follow-up; Female Cancer Survivors; Fertility Preservation Techniques

• Study Type: Observational
• Enrollment (Estimated): 102

Contacts and Locations

• Study Contact: Name: CABRY-GOUBET Rosalie, Pr; Phone Number: 33+3 22 08 80 00; Email: cabry.rosalie@chu-amiens.fr

Study Locations

• France
  • Amiens, France
    • Recruiting
    • CHU Amiens Picardie
    • Contact: Rosalie Cabry, Pr; Email: Cabry.Rosalie@chu-amiens.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients are recruited during follow-up consultations as part of the establishment of a fertility observatory within the Department of Medicine and Reproductive Biology at CHU Amiens Picardie

Description

Inclusion Criteria:

• Women
• Aged between 18 and 47 years
• Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment
• Having undergone a medical fertility preservation consultation
• Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine
• Currently in remission
• Having expressed non-opposition to participation in the study

Exclusion Criteria:

• Absence of remission
• Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)
• Decline to participate in the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of an identifiable reproductive outcome	Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Type of fertility preservation method performed		1 year
Time interval (in months) between diagnosis and fertility preservation		1 year
Correlation between Age and occurance of an identifiable reproductive outcome	Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project	1 year
Time interval (in months) between fertility preservation and initiation of potentially gonadotoxic treatment		1 year
Number of type of cancer associated with identifiable reproductive outcome	Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project	1 year
Correlation between type of treatment and occurence of an identifiable reproductive outcome	Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project	1 year
Correlation between family status and occurence of an identifiable reproductive outcome	Identifiable reproductive outcome are Spontaneous pregnancy, Use of preserved gametes or ovarian tissue (whether or not resulting in pregnancy), Use of donor oocytes, Discontinuation of the parenthood project	1 year
Time interval (in months) between completion of treatment and pregnancy attempt (spontaneous or medically assisted)		1 year
Actual utilization rate of preserved material		1 year
Success rate of reuse attempts		1 year
Proportion of patients who ultimately did not pursue parenthood		1 year

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens

Study record dates

Study Major Dates

• Study Start (Estimated): December 17, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: November 17, 2025
• First Submitted That Met QC Criteria: December 16, 2025
• First Posted (Estimated): December 31, 2025

Study Record Updates

• Last Update Posted (Estimated): January 16, 2026
• Last Update Submitted That Met QC Criteria: January 15, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Oncology; Reproductive health; Fertility preservation; Live birth rate; Assisted reproductive technology; Psychological impact; Reproductive outcomes; Patient follow-up; Cancer remission; Fertility counseling; Fertility observatory; Female cancer survivors; Fertility preservation techniques
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: PI2025_843_0156

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No